#United States #New York #Class Action #Gross Law Firm #Skye Bioscience

Skye Bioscience Shareholders: Important Class Action Update

If you are a shareholder of Skye Bioscience, Inc. (NASDAQ: SKYE) and believe you have incurred financial losses, this is an important message for you. The Gross Law Firm has announced a class action lawsuit aimed at recovering losses for investors who purchased shares during a specified class period.

Background of the Case

On December 11, 2025, The Gross Law Firm issued a notice indicating that shareholders who acquired SKYE shares between November 4, 2024, and October 3, 2025, are encouraged to participate in a class action. This legal initiative arises from allegations that the company engaged in misleading practices regarding its lead product candidate, nimacimab.

The firm alleges that Skye Bioscience provided materially false statements that conveyed an inflated perception of nimacimab's effectiveness, leading investors to have unrealistic expectations about its clinical and commercial prospects. Such statements, the lawsuit contends, failed to disclose critical information that could have influenced investor decisions significantly.

Key Details of the Class Action

• - Class Period: November 4, 2024, to October 3, 2025.
• - Allegations: Defendants allegedly misrepresented the efficacy of nimacimab, overstating its clinical and regulatory promise.
• - Registration Deadline: Interested shareholders must register by January 16, 2026, to be considered as potential lead plaintiffs. However, it is important to note that being named as a lead plaintiff is not a prerequisite for participating in the recovery process.

What Shareholders Need to Do

Shareholders are urged to register promptly, as they will be enrolled in a monitoring software for case updates. Participation in this class action involves no financial obligation, and there is no cost incurred for registering. This initiative allows shareholders to monitor their status throughout the litigation process, ensuring they remain informed every step of the way.

To register, please visit the following link: Register Here.

Why Choose The Gross Law Firm?

The Gross Law Firm is well-regarded nationally for its expertise in class action lawsuits. Their mission is centered around protecting investors' rights against deceitful corporate practices. They are committed to holding corporations accountable for misleading statements that lead to financial harm to their investors. The firm’s dedication to responsible business practices and corporate citizenship reinforces their role as advocates for shareholders.

If you feel you have been affected by the actions of Skye Bioscience, do not hesitate to reach out and determine how you can participate in the recovery process. For further inquiries, contact The Gross Law Firm directly at:

• - Email: [email protected]
• - Phone: (646) 453-8903.

In an environment where transparency is crucial for investor trust, legal recourse provides a vital avenue to seek justice and ensure that such practices do not continue unchecked. Shareholders should stay informed and proactive as they navigate this class action litigation.

Conclusion

The ongoing litigation against Skye Bioscience is a reminder of the need for diligence and the rights of investors to seek redress for potential wrongs committed by corporations. If you are a shareholder, your participation could be a critical step toward accountability and recovery. Ensure you register before the deadline to protect your rights as an investor.